Skip to main content
The Journal of Biological Chemistry logoLink to The Journal of Biological Chemistry
. 2011 Jun 8;286(32):28138–28149. doi: 10.1074/jbc.M110.204099

G Protein Binding Sites on Calnuc (Nucleobindin 1) and NUCB2 (Nucleobindin 2) Define a New Class of Gαi-regulatory Motifs*

Mikel Garcia-Marcos ‡,1, Patrick S Kietrsunthorn , Honghui Wang , Pradipta Ghosh §,2, Marilyn G Farquhar ‡,3
PMCID: PMC3151059  PMID: 21653697

Abstract

Heterotrimeric G proteins are molecular switches modulated by families of structurally and functionally related regulators. GIV (Gα-interacting vesicle-associated protein) is the first non-receptor guanine nucleotide exchange factor (GEF) that activates Gαi subunits via a defined, evolutionarily conserved motif. Here we found that Calnuc and NUCB2, two highly homologous calcium-binding proteins, share a common motif with GIV for Gαi binding and activation. Bioinformatics searches and structural analysis revealed that Calnuc and NUCB2 possess an evolutionarily conserved motif with sequence and structural similarity to the GEF sequence of GIV. Using in vitro pulldown and competition assays, we demonstrate that this motif binds preferentially to the inactive conformation of Gαi1 and Gαi3 over other Gα subunits and, like GIV, docks onto the α3/switch II cleft. Calnuc binding was impaired when Lys-248 in the α3 helix of Gαi3 was replaced with M, the corresponding residue in Gαo, which does not bind to Calnuc. Moreover, mutation of hydrophobic residues in the conserved motif predicted to dock on the α3/switch II cleft of Gαi3 impaired the ability of Calnuc and NUCB2 to bind and activate Gαi3 in vitro. We also provide evidence that calcium binding to Calnuc and NUCB2 abolishes their interaction with Gαi3 in vitro and in cells, probably by inducing a conformational change that renders the Gαi-binding residues inaccessible. Taken together, our results identify a new type of Gαi-regulatory motif named the GBA motif (for Gα-binding and -activating motif), which is conserved across different proteins throughout evolution. These findings provide the structural basis for the properties of Calnuc and NUCB2 binding to Gα subunits and its regulation by calcium ions.

Keywords: Calcium-binding Proteins, G Proteins, Protein Motifs, Protein-Protein Interactions, Signal Transduction, Non-receptor GEF

Introduction

Recently it has become clear that in addition to G protein-coupled receptors and Gβγ subunits, the function of the Gα subunits of heterotrimeric G proteins is controlled by accessory proteins that regulate their activity and/or localization (13). The first group of such regulators to be described was the regulators of G protein signaling (RGS)4 protein family, which serve as GTPase-activating proteins for Gαi, Gαq, and Gα12 subunits via a 120-aa conserved domain, the “RGS box” (4, 5). Subsequent studies revealed another group of regulatory proteins with GDI activity for Gαi subunits, which have a common signature motif, i.e. the GoLoco or G protein-regulatory (GPR) motif (1, 6, 7). Both the RGS box (8, 9) and the GoLoco/GPR motif (10) have been structurally resolved by X-ray chrytallography, and their critical roles in metabolism, cell division, and cardiovascular function, among others, have made them emerging pharmacological targets (11, 12). We recently described another Gα-interacting protein, GIV (13), and showed that it is a GEF that activates Gα subunits and mediates its biological functions via a defined motif (14) with structural similarity to the synthetic GEF peptide KB-752 (15). GIV is a metastasis-related protein (16) that enhances PI3K-Akt signaling and promotes macrophage, endothelial, epithelial, and tumor cell migration (1719).

We identified Calnuc (nucleobindin 1 or NUCB1) as a Gα-binding protein in a yeast two-hybrid screen using Gαi3 as bait (21). Calnuc, the most abundant protein in the Golgi (24) and the major calcium-binding protein within the Golgi lumen (2123), regulates intracellular calcium stores via its two EF-hands (22). In addition, we have shown previously that there is a significant soluble pool of Calnuc in the cytosol (21, 25), which interacts with Gαi3 in vivo on the surface of Golgi membranes as demonstrated by FRET and live cell imaging (26). The role of cytosolic Calnuc as a G protein regulator was further substantiated by the finding that it controls the intracellular localization of Gαi subunits in neuroendocrine cells (27). However, the mechanism by which Calnuc binds or regulates Gαi subunits remains unknown. Here we identified a conserved motif in Calnuc and the highly homologous protein NUCB2 (nucleobindin 2 or NEFA) (20) with similarity to the GEF motif of GIV and characterized how this motif binds and regulates Gαi subunits. These findings help define a new class of structurally defined G protein regulatory motifs and provide insights into how the interaction between Gαi3 and Calnuc is regulated.

EXPERIMENTAL PROCEDURES

Reagents and Antibodies

The peptide corresponding to the Calnuc Gαi-binding motif, i.e. 309RLVTLEEFLASTQRKE324 (Calnuc-(309–324) peptide, >95% purity), was synthesized and purified as described (28). The control peptide (EVVTLQQALEESNKLT, >95% purity) used in our experiments, corresponding to the GEF sequence of GIV with a F1685A mutation that abolishes binding and GEF activity (14), was custom-made by Genway Biotech (San Diego). NUCB2 cDNA was obtained from Open Biosystems. The sources of the remainder of the reagents and antibodies used were described previously (14, 17, 29).

Plasmid Constructs, Mutagenesis, and Protein Expression

Cloning of GST- or His-tagged Gαi1, Gαi2, Gαi3, and Gαo was described previously (14, 29). Full-length rat Calnuc and NUCB2-(173–333), containing the putative Gα-binding motif, were inserted between the BamHI and XhoI restriction sites of the pGEX-4T-1 vector to generate GST-Calnuc and GST-NUCB2, respectively. His-tagged full-length Calnuc-(1–459) and Calnuc-(171–459) (CalnucΔN) and full-length rat NUCB2 were cloned using the ligation-independent cloning vector pMCSG7 exactly as described previously (30). Cloning of rat Gαi3 with three FLAG sequences fused to the C terminus of the protein (Gαi3-FLAG) using the mammalian expression vector p3XFLAG-CMV-14 was described previously (29). Cloning Calnuc into pcDNA3.1 with a CFP fused at the C terminus and lacking the signal sequence (aa 2–25, ΔSS-Calnuc-CFP) was described previously (26). Calnuc, NUCB2, and Gαi3 mutants were generated using specific primers (sequences available upon request) following the manufacturer's instructions (QuikChange II, Stratagene, San Diego). Purification of GST- or His-tagged Gαi1, Gαi2, Gαi3, and Gαo was carried out following described protocols (14, 17, 29). A modified protocol was used for the purification of GST-Calnuc, His-Calnuc, His-CalnucΔN, His-NUCB2, and GST-NUCB2. Briefly, induction of protein expression for these constructs was carried out using the autoinduction protocol described by Studier (31). Briefly, BL21(DE3) cells were incubated at 37 °C for 5 h (∼A600 = 0.6–0.8), switched to 23 °C for 19 h, and harvested at A600 = 5–15. Cell lysis was carried out in a French press, and the remainder of the purification was performed as described (14, 17, 29) with an additional purification step by gel filtration chromatography using a Superdex 200 column attached to an AKTA FPLC machine. Fractions containing the protein of interest were pooled and in some cases concentrated using an Amicon Ultra filter (10,000 Da cut-off, Millipore). His-NUCB2 was toxic in Escherichia coli, resulting in slow growth and low yields of protein (∼0.3 mg/liter bacterial culture) compared with His-Calnuc (∼3 mg/liter bacterial culture), His-CalnucΔN (∼10–15 mg/liter bacterial culture), or GST-NUCB2-(173–333) (∼8 mg/liter bacterial culture).

In Vitro Protein Binding (Pulldown) Assays

This assay was performed essentially as described previously (14, 17, 29). Briefly, purified GST fusion proteins or GST alone (3–20 μg) was immobilized on glutathione-Sepharose beads and incubated in binding buffer (50 mm Tris-HCl, pH 7.4, 100 mm NaCl, 0.4% (v:v) Nonidet P-40, 10 mm MgCl2, 5 mm EDTA, 2 mm DTT, and protease inhibitor mixture) containing either 30 μm GDP or 30 μm GDP, 30 μm AlCl3, and 10 mm NaF or 30 μm GTPγS for 90 min at room temperature. Solubilized proteins from ∼750 μg rat brain membranes or 2–6 μg purified His-tagged proteins were added to each tube, and binding reactions were carried out overnight at 4 °C with constant tumbling. Beads were washed four times with 1 ml of wash buffer (4.3 mm Na2HPO4, 1.4 mm KH2PO4, pH 7.4, 137 mm NaCl, 2.7 mm KCl, 0.1% (v:v) Tween 20, 10 mm MgCl2, 5 mm EDTA, and 2 mm DTT supplemented with GDP, GDP plus AlCl3, and NaF or GTPγS as during binding) and boiled in sample buffer for SDS-PAGE.

Immunoblotting

Proteins samples were separated on 10% SDS-PAGE and transferred to PVDF membranes (Millipore, Billerica, MA). In experiments using His-Calnuc, His-CalnucΔN, or His-NUCB2 all electrophoretic steps were performed in the presence of 4 m urea, which increased the sensitivity of the immunodetection. Membranes were blocked with PBS supplemented with 5% nonfat milk before sequential incubation with primary and secondary antibodies. Infrared imaging was performed using an Odyssey imaging system (LI-COR Biosciences, Lincoln, NE). Primary antibodies were diluted as follows: anti-His, 1:2000; anti-Gαi3, 1:300, anti-Gαo, 1:500; anti-Gαs, 1:250.

Steady-state GTPase Assay

This assay was performed as described previously (14, 29). Briefly, His-Gαi3 (100 nm) was preincubated with different concentrations of His-CalnucΔN-(171–459) or GST-NUCB2 (173–333) for 15–30 min at 30 °C in assay buffer (20 mm Na-HEPES, pH 8, 100 mm NaCl, 1 mm EDTA, 2 mm MgCl2, 1 mm DTT, and 0.05% (w:v) C12E10). His-CalnucΔN and GST-NUCB2-(173–333) were used instead of full-length His-Calnuc or GST-NUCB2 because the protein concentrations used in these experiments were achievable for only the truncated proteins, which express at higher yields in bacteria. GTPase reactions were initiated at 30 °C by adding an equal volume of assay buffer containing 1 μm [γ-32P]GTP (∼50 cpm/fmol). Duplicate aliquots (50 μl) were removed at different time points, and reactions were stopped with 950 μl of ice-cold 5% (w/v) activated charcoal in 20 mm H3PO4, pH 3. Samples were then centrifuged for 10 min at 10,000 × g, and 500 μl of the resultant supernatant was scintillation-counted to quantify released [32P]Pi. To determine the specific Pi produced, the background [32P]Pi detected at 10 min in the absence of G protein was subtracted from each reaction.

GTPγS Binding Assay

GTPγS binding was measured using a filter binding method. His-Gαi3 (100 nm) was preincubated in the presence or absence of 45 μm His-CalnucΔN for 30 min at 30 °C in assay buffer (20 mm Na-HEPES, pH 8, 100 mm NaCl, 1 mm EDTA, 25 mm MgCl2, 1 mm DTT, and 0.05% (w:v) C12E10). Reactions were initiated at 30 °C by adding an equal volume of assay buffer containing 1 μm [35S] GTPγS (∼50 cpm/fmol). Duplicate aliquots (25 μl) were removed at different time points, and binding of radioactive nucleotide was stopped by the addition of 3 ml of ice-cold wash buffer (20 mm Tris-HCl, pH 8.0, 100 mm NaCl, and 25 mm MgCl2). The quenched reactions were rapidly passed through BA-85 nitrocellulose filters (GE Healthcare) and washed with 4 ml of wash buffer. Filters were dried and subjected to liquid scintillation counting. Experiments designed to study the effect of Ca2+ were performed as described above except that no EDTA was used and different concentrations of CaCl2 were added.

Cell Culture, Transfection, and Immunoprecipitation

COS-7 cells were grown at 37 °C in DMEM supplemented with 10% FBS, 100 units/ml penicillin, 100 μg/ml streptomycin, 1% l-glutamine, and 5% CO2 and transfected with plasmids encoding for ΔSS-Calnuc-CFP (lacking the signal sequence; aa 2–25, 0.5 μg) and Gαi3-FLAG (6 μg) or vector control (6 μg) using GeneJuice as described previously (29). 36 h after transfection the cells were maintained overnight in DMEM alone (∼1.8 mm calcium) and then stimulated or not with 1 μm thapsigargin or 100 μm ATP for 90 s, rinsed quickly twice with ice-cold PBS, scraped into lysis buffer (20 mm HEPES, pH 7.2, 5 mm Mg(CH3COO)2, 125 mm K(CH3COO), 0.4% Triton X-100, and 1 mm DTT) supplemented with phosphatase (Sigma) and protease (Roche Applied Science) inhibitor mixtures, passed through a 28-gauge needle at 4 °C, and cleared (10,000 × g for 10 min). COS-7 cell lysates (∼1–2 mg) were incubated for 2.5 h at 4 °C with 2 μg anti-FLAG mAb (Sigma) followed by incubation with protein G-agarose beads (GE Healthcare) at 4 °C for an additional 45 min. Beads were washed four times with 1 ml of wash buffer (4.3 mm Na2HPO4, 1.4 mm KH2PO4, pH 7.4, 137 mm NaCl, 2.7 mm KCl, 0.1% (v:v) Tween 20, 10 mm MgCl2, 5 mm EDTA, and 2 mm DTT), and the bound immune complexes were eluted by boiling in SDS sample buffer.

Preparation of Detergent-soluble Extracts from Rat Brain Membranes

Isolation of rat brain membranes was adapted from a fractionation procedure described previously for liver (32). Briefly, rat brains were homogenized in 10 mm HEPES-KOH, pH 7.4, 5 mm EDTA, and 0.5 m sucrose with a Teflon-glass homogenizer and spun down at 1,000 × g for 10 min to sediment unbroken tissue and nuclei, and the resulting supernatant (postnuclear supernatant) was collected. Crude membranes were sedimented from the postnuclear supernatant by centrifugation at 100,000 × g, aliquoted, and stored at −80 °C. Rat brain membrane lysates were freshly prepared prior to the pulldown experiments presented in Fig. 4 by solubilizing ∼750 μg of protein/condition in binding buffer (50 mm Tris-HCl, pH 7.4, 100 mm NaCl, 0.4% (v:v) Nonidet P-40, 10 mm MgCl2, 5 mm EDTA, 2 mm DTT, and protease inhibitor mixture) for ∼2 h at 4 °C. Lysates were cleared (14,000 × g for 10 min) before use in subsequent experiments.

FIGURE 4.

FIGURE 4.

Calnuc binds to different Gαi subunits but not to Gαo or Gαs. A, Upper panel, GST-Calnuc binds Gαi3 (lane 3) but not Gαo (lane 7) or Gαs (lane 11) from rat brain membrane lysates in the presence of GDP but not GDP·AlF4 (lanes 4, 8, and 12). Solubilized proteins from 750 μg of rat brain membranes were incubated with ∼20 μg of purified GST (lanes 2, 6, and 10) or GST-Calnuc (lanes 3, 4, 7, 8, 11, 12, and 13) immobilized on glutathione beads in the presence of GDP (30 μm; lanes 2, 3, 6, 7, 10, and 11) or GDP and AlF4 (AlCl3, 30 μm; NaF, 10 mm; lanes 4, 8, and 12). An additional control without rat brain membrane lysate was performed to validate Gαs antibody specificity (lane 13). Input (lanes 1, 5, and 9), 10% of the membrane lysate. No binding of Gαi3, Gαo, or Gαs to the negative control GST was detected (lanes 2, 6, and 10). The arrows (lanes 1, 3, 5, and 9) denote the specific bands corresponding to the different Gα subunits (including the long and short splice forms of Gαs, lane 9), and the star (lanes 11, 12, and 13) denotes a nonspecific band recognized by the Gαs antibody. IB, immunoblot. Lower panel, equal loading of GST proteins was confirmed by Ponceau S staining. B, His-CalnucΔN binds to GST-Gαi1·GDP (lane 3) and GST-Gαi3·GDP (lane 5) to a greater extent (∼20-fold) than to GST-Gαi2·GDP (lane 4) and binds only marginally to either of the Gαi subunits preloaded with GDP·AlF4 (lanes 6, 7, and 8) or GST (lane 2). 10 μg of His-CalnucΔN was incubated with 15 μg of GST (lane 2), GST-Gαi1 (lanes 3 and 6), GST-Gαi2 (lanes 4 and 7), or GST-Gαi3 (lanes 5 and 8) preloaded with GDP (lanes 2–5) or GDP·AlF4 (lanes 6–8), immobilized on glutathione beads, and analyzed as described for Fig. 2A. Input (lane 1), 1 μg of His-CalnucΔN.

Other Methods

Protein structure analysis and visualization was performed using ICM-Browser-Pro software (Molsoft Inc., San Diego). Data presented in Figs. 2C, 7C, and 8D and supplemental Fig. S4 were curve-fitted by nonlinear regression using Prism 4.0. (San Diego) to determine the Kd, EC50, and IC50 values.

FIGURE 2.

FIGURE 2.

Calnuc and NUCB2 bind inactive but not active Gαi3. A, His-Gαi3·GDP (lane 4) but not His-Gαi3·GDP·AlF4 (lane 5) or His-Gαi3·GTPγS (lane 6) binds to GST-Calnuc. No binding of Gαi3 to GST was detected under any of the conditions tested (lanes 1–3). 6 μg of His-Gαi3 preloaded with GDP (lanes 1 and 4), GDP and AlF4 (lanes 2 and 5), or GTPγS (30 μm, lanes 3 and 6) were incubated with ∼20 μg of purified GST (lanes 1–3) or GST-Calnuc (lanes 4–6) immobilized on glutathione beads. After extensive washing, bound proteins were separated by SDS-PAGE and analyzed by immunoblotting (IB) for His. Equal loading of GST proteins was confirmed by Ponceau S staining (middle panel), and equal loading of His-Gαi3 by His immunoblotting (lower panel). B, GST-Gαi3·GDP (lane 5) but not GST-Gαi3·GDP·AlF4 (lane 3) or GST (lanes 2 and 4) binds His-NUCB2. 10 μg of His-NUCB2 was incubated with ∼15 μg of purified GST (lanes 2 and 4) or GST-Gαi3 (lanes 3 and 5) preloaded with GDP (lanes 4 and 5) or GDP·AlF4 (lanes 2 and 3) immobilized on glutathione beads and analyzed as described in A. Input (lane 1), 1 μg of His-NUCB2. C, His-Gαi3·GDP binds to GST-Calnuc and GST-NUCB2-(173–333) with a Kd of 3.7 ± 1.2 μm (n = 4) and 1.0 ± 0.3 μm (n = 3), respectively. Increasing concentrations of His-Gαi3·GDP (0.3, 0.5, 1, 1.5, 3, 5, 10, and 20 μm) were incubated with 20 μg of GST-Calnuc (closed circles) or GST-NUCB2 (open circles) and analyzed as in A. His-Gαi3 binding was determined by quantitative immunoblotting using an Odyssey infrared imaging system, and data were fitted to a nonlinear, one-site binding hyperbola (solid lines) using Prism 4.0.

FIGURE 7.

FIGURE 7.

Calnuc and NUCB2 activate Gαi3. A, His-CalnucΔN WT but not the L313A/L317A (LL/AA) mutant increases the steady-state GTPase activity of His-Gαi3. The steady-state GTPase activity of purified His-Gαi3 (50 nm) was determined in the absence (closed circles) or presence of 60 μm purified wild-type His-CalnucΔN (open circles) or His-CalnucΔN L315A/L319A mutant (inverted triangles) by quantifying the amount of [γ-32P]GTP (0.5 μm, ∼50 cpm/fmol) hydrolyzed at the indicated time points. Results are shown as mean ± S.D. of one representative experiment of three performed in duplicate. B, WT GST-NUCB2-(173–333) but not the L315A/L319A mutant increases the steady-state GTPase activity of His-Gαi3. The steady-state GTPase activity of purified His-Gαi3 (100 nm) was determined exactly as described in A except that 50 μm NUCB2 was used. C, dose-dependent activation of His-Gαi3 by His-CalnucΔN and GST-NUCB2. The steady-state GTPase activity of purified His-Gαi3 was determined in the presence of the indicated amounts of purified wild-type His-CalnucΔN (closed circles) or GST-NUCB2 (open circles) by quantification of the amount of [γ-32P]GTP (0.5 μm, ∼50 cpm/fmol) hydrolyzed in 10 min. Data expressed as percent of GTP hydrolyzed by the G protein alone (0 μm) were fitted to a nonlinear, one-site hyperbola (solid line) using Prism 4.0. Results are shown as mean ± S.E. of the indicated number of experiments (n). D, His-CalnucΔN increases the rate of GTPγS binding of His-Gαi3. Nucleotide exchange activity of purified His-Gαi3 (50 nm) was determined in the absence (closed circles) or presence of 25 μm purified wild-type His-CalnucΔN (open circles) by quantification of the amount of [35S]GTPγS (0.5 μm, ∼50 cpm/fmol) bound at the indicated time points. No significant binding of GTPγS binding was detected in the absence of His-Gαi3 or the presence of His-CalnucΔN alone (not shown). Results are shown as mean ± S.D. of one representative experiment of four performed in duplicate.

FIGURE 8.

FIGURE 8.

Effect of Ca2+ on Calnuc and NUCB2 binding to Gαi3. A, structural view of the Gαi-binding motif of Calnuc in the calcium-bound conformation. The coordinates of the NMR-resolved structure of Calnuc were extracted from the Protein Data Bank (ID code: 1SNL) and visualized using ICM-Browser-Pro. Residues of the Gαi-binding motif of Calnuc required for the interaction with Gαi3 (Fig. 6) are not solvent-exposed in the calcium-bound conformation of Calnuc because they were utilized to make an intramolecular contact. B, His-Gαi3 binding to GST-Calnuc is virtually abolished in the presence of CaCl2. 6 μg of His-Gαi3 preloaded with GDP (30 μm) was incubated with ∼20 μg of purified GST (lanes 1 and 3) or GST-Calnuc (lanes 2 and 4) immobilized on glutathione beads in the presence (lanes 3 and 4) or absence (lanes 1 and 2) of 8 mm CaCl2 (∼3 mm free Ca2+). Subsequent steps were performed as described in the legend for Fig. 2A. C, binding of GST-Gαi3 to His-NUCB2 is virtually abolished in the presence of CaCl2. 10 μg of His-NUCB2 was incubated with purified GST (lanes 1 and 3) or GST-Gαi3 (lanes 2 and 4) immobilized on glutathione beads in the presence (lanes 3 and 4) or absence (lanes 1 and 2) of 8 mm CaCl2 (∼3 mm free Ca2+). Subsequent steps were performed as described in the legend for Fig. 2B. Input (lane 5), 1 μg of His-NUCB2. D, activation of His-Gαi3 by His-CalnucΔN is inhibited by CaCl2 in a dose-dependent manner. Nucleotide exchange activity of purified His-Gαi3 (50 nm) at the indicated concentrations of CaCl2 was determined in the absence (closed circles) or presence of 25 μm purified wild-type His-CalnucΔN (open circles) by quantification of the amount of [35S] GTPγS (0.5 μm, ∼50 cpm/fmol) bound at 20 min. Results are shown as mean ± S.D. of one representative of three independent experiments performed in duplicate. CaCl2 does not affect the basal activity of Gαi3 alone (closed circles). E, stimulation of COS-7 cells with thapsigargin or ATP inhibits the interaction of Calnuc with Gαi3. Upper panels, co-immunoprecipitation of ΔSS-Calnuc-CFP but not Gβγ with Gαi3-FLAG is dramatically reduced after stimulation with thapsigargin (TG) (lane 3) or ATP (lane 4) compared with unstimulated cells (lane 2). No ΔSS-Calnuc-CFP or Gβγ was detected in FLAG immunoprecipitates of cells transfected with vector control (lane 1). COS-7 cells were transfected with empty vector (lane 1) or plasmids encoding Gαi3-FLAG and ΔSS-Calnuc-CFP (lanes 2, 3, and 4), stimulated with thapsigargin (lane 3) or ATP (lane 4) and immunoprecipitated (IP) as described under “Experimental Procedures.” Immunoprecipitation was followed by immunoblotting (IB) for FLAG (Gαi3), GFP (ΔSS-Calnuc-CFP), and Gβ. Equal IgG loading was confirmed by Ponceau S staining. Lower panels, aliquots of the lysates (10%) were analyzed by immunoblotting to confirm equal loading of Gαi3, Calnuc, Gβ, and α-tubulin. F, schematic illustration of how Ca2+ binding to Calnuc mediates a molecular rearrangement that prevents Gαi3 binding. Left, in the absence of Ca2+, the Calnuc calcium-binding domain (black line with red semicircles) is disordered (34) allowing the exposure of the Gαi-binding motif (aa 309–324 (blue box)). Right, in the presence of Ca2+, Calnuc undergoes a conformational change such that residues in the Gαi-binding motif (blue box) make an intramolecular interaction (dotted lines) and binding to Gαi3 is hindered because the Gαi-binding motif is not exposed. Presumably the same occurs for the NUCB2 Gαi-binding motif (aa 311–326) upon calcium binding.

RESULTS

Identification of a Putative Gα-interacting Motif in Calnuc and NUCB2

By manual examination of the Calnuc sequence, we noticed a region with significant similarity to the GEF motif of GIV and two synthetic peptides with GEF activity, KB-752 (15) and GSP (33) (Fig. 1A). This motif (aa 309–324) overlaps with the C-terminal part of the second EF-hand of Calnuc and is also found in NUCB2, a protein highly homologous to Calnuc (62% aa sequence identity). Phylogenetic analysis revealed that this motif is evolutionarily conserved in both Calnuc and NUCB2 proteins from invertebrates to humans (supplemental Fig. S1). In addition, the structure of this motif extracted from the NMR coordinates of the calcium-binding domain of Calnuc (34) is very similar to the established crystal structure of the KB-752 peptide bound to Gαi1 (15) and the homology-based structural prediction for the GEF motif of GIV bound to Gαi3 (14) (Fig. 1B). These observations indicate that Calnuc and NUCB2 possess an evolutionarily conserved motif with structural similarity to the GEF motif of GIV and GIV-related peptides that display GEF activity.

FIGURE 1.

FIGURE 1.

Identification of a putative Gα-binding motif in Calnuc and NUCB2. A, a sequence at the end of the Calnuc (aa 309–324) and NUCB2 (aa 311–326) second EF-hand shows a similarity to the GEF motif of GIV (aa 1678–1693) and the synthetic KB-752 and GSP peptides. Rat Calnuc, rat NUCB2, and human GIV sequences were obtained from the NCBI and aligned with the KB-752 (15) and GSP (33) sequences using ClustalW. Conserved identical residues are shaded in black and similar residues in gray. A consensus sequence of 7 aa based on this alignment and the phylogenetic analysis of Calnuc (Fig. S1) and GIV (14) is indicated. B, the Calnuc putative Gαi-binding motif has a structural similarity to the KB-752 peptide and the GEF motif of GIV. The coordinates of the Calnuc putative Gα-binding sequence (aa 309–320 (red)) were extracted from the Protein Data Bank (ID code: 1SNL) and the coordinates for the GEF motif of GIV (aa 1678–1689 (green)) from a previously described homology model (14). Both were threaded over the structure of KB-752 (yellow) in complex with Gαi1 (blue) (Protein Data Bank ID code: 1Y3A) using ICM-Browser-Pro. The Calnuc putative Gαi-binding motif, the GEF motif of GIV, and KB-752 form a helix in which the side chains of hydrophobic residues corresponding to positions 3, 6, and 7 from the consensus sequence depicted in A dock onto the α3/SwII hydrophobic cleft of the Gαi subunits (cyan surface).

Calnuc and NUCB2 Bind Preferentially to Inactive Gαi3

Based on the sequence and structural similarities described above, we reasoned that Calnuc and NUCB2 might have similar Gα binding properties to those of the GEF motif of GIV and related peptides that bind specifically to inactive GDP-bound Gαi subunits. We found that this was indeed the case for both Calnuc (Fig. 2A) and NUCB2 (Fig. 2B). GST-Calnuc bound robustly to inactive, GDP-loaded His-Gαi3 but not to the G protein when it was activated by either GDP·AlF4 or GTPγS loading (Fig. 2A). Similar results (data not shown) were obtained in pulldown assays using GST-Gαi3 and His-tagged Calnuc or CalnucΔN-(171–459), an N-terminally truncated construct containing the putative Gα-binding motif. Similarly, His-NUCB2 showed robust binding to GST-Gαi3 in the presence of GDP but not in the presence of GDP·AlF4 (Fig. 2B). The interaction of GST-Calnuc and GST-NUCB2-(173–333) (containing the putative Gα-binding motif), with GDP-loaded His-Gαi3, has a dissociation constant (Kd) of 3.7 ± 1.2 and 1.0 ± 0.3 μm, respectively (Fig. 2C). These results indicate that, much like GIV and the GIV-related peptides, binding of Calnuc and NUCB2 to Gαi3 is state-dependent with a marked preference for the inactive conformation.

Calnuc and NUCB2 Bind to the α3/Switch II Cleft on Gαi·GDP

Next we performed competition assays to determine whether Calnuc and NUCB2 shared a common binding site on Gαi3 with the synthetic KB-752 peptide and GIV, which bind to the hydrophobic cleft circumscribed by the α3 helix and “switch II” (SwII) (14, 15). We found that increasing concentrations of KB-752, but not a control peptide (see “Experimental Procedures”), decreased His-Gαi3 binding to GST-Calnuc (Fig. 3A). Similarly, increasing concentrations of a peptide (aa 309–324) corresponding to the putative Gαi binding sequence of Calnuc, but not a control peptide, decreased the amount of His-GIV-CTs (aa 1660–1870, containing the GEF motif of GIV) that bound to GST-Gαi3 (Fig. 3B). We also performed similar competition assays with GST-NUCB2-(173–333) and found that it also competed with the KB-752 peptide (Fig. 3C) or His-GIV-CTs (Fig. 3D) but not with their respective controls for binding to Gαi3. Taken together these results suggest that Calnuc and NUCB2 bind specifically to the α3/SwII cleft of Gαi3·GDP via the newly identified motif.

FIGURE 3.

FIGURE 3.

Calnuc and NUCB2 compete with KB-752 and GIV for binding to inactive Gαi3. A, the KB-752 peptide but not a control peptide (see “Experimental Procedures”) competes with GST-Calnuc for binding to His-Gαi3·GDP. Increasing concentrations of the KB-752 peptide (0, 0.1, 1, 3, 10, and 30 μm) or control peptide (30 μm) were incubated with 20 μg (∼0.9 μm) of GST-Calnuc in the presence of 6 μg (∼0.5 μm) of His-Gαi3 preloaded with GDP and analyzed as described in the legend for Fig. 2A. No binding of His-Gαi3·GDP GST was detected. Input, 0.2 μg of His-Gαi3·GDP. IB, immunoblot. B, a peptide corresponding to the Gα-binding motif of Calnuc 309–324 peptide, but not a control peptide, competes with His-GIV-CTs (aa 1660–1870, containing the GIV GEF motif) for binding to GST-Gαi3·GDP. Increasing concentrations of Calnuc 309–324 peptide (0, 0.3, 1, 3, 10, 30, and 100 μm) or a control peptide (100 μm) were incubated with 3 μg (∼250 nm) of GST-Gαi3 preloaded with GDP immobilized on glutathione beads in the presence of 2 μg (∼250 nm) of His-GIV-CTs and analyzed as described in the legend for Fig. 2A. No binding of His-GIV-CTs to GST is detected. Input, 0.1 μg of His-GIV-CTs. C, the KB-752 peptide but not a control peptide (see “Experimental Procedures”) competes with GST-NUCB2 for binding to His-Gαi3·GDP. Increasing concentrations of the KB-752 peptide (0, 0.1, 1, 3, 10, and 30 μm) or the control peptide (30 μm) were incubated with 20 μg (∼1.7 μm) of GST-NUCB2 in the presence of 6 μg (∼0.5 μm) of His-Gαi3 preloaded with GDP and analyzed as described in the legend for Fig. 2A. No binding of His-Gαi3·GDP to GST is detected. Input, 0.2 μg of His-Gαi3·GDP. D, His-GIV-CTs WT but not the Gαi binding-deficient His-GIV-CTs F1685A (FA) (14) competes with GST-NUCB2 for binding to His-Gαi3·GDP. Increasing concentrations of His-GIV-CTs WT (∼0, 0.26, 0.5, 0.8, 1.3, and 2 μm) or His-GIV-CTs F1685A (2 μm) were incubated with 20 μg (∼1.7 μm) of GST-NUCB2 in the presence of 5 μg (∼0.4 μm) of His-Gαi3 preloaded with GDP and analyzed as described in the legend for Fig. 2A. No binding of His-Gαi3·GDP to GST was detected. Input, 0.15 μg of His-Gαi3·GDP.

Characterization of Calnuc Specificity for Gα Subunits

We have previously shown that Calnuc can interact with Gαi, Gαo, and Gαs but not Gα12/13 or Gαq in yeast two-hybrid assays (21). Next we investigated the relative strength of the interaction of Calnuc with Gαi, Gαo, and Gαs using in vitro protein-protein binding assays. We found that GST-Calnuc bound GDP-loaded Gαi3 from rat brain membrane lysates, whereas binding of Gαo was very weak and binding of Gαs was undetectable (Fig. 4A). We further performed pulldown assays using purified GST-Gαi1, GST-Gαi2, and GST-Gαi3 and His-CalnucΔN to investigate whether Calnuc binds to other Gαi subunits. We used CalnucΔN instead of full-length Calnuc because initial experiments indicated that they shared virtually identical Gαi binding properties (data not shown). We found that His-CalnucΔN binds strongly to GDP-loaded GST-Gαi1 and GST-Gαi3 but showed significantly less binding to Gαi2 (Fig. 4B). These results indicate that the binding preference of Calnuc for Gα subunits is Gαi1 ≈ Gαi3 > Gαi2 ⋙ Gαo ≥ Gαs.

Lys-248 in Gαi3 Determines the Preferential Binding of Calnuc to Gαi3 versus Gαo

Recently we found that a single residue differing between the Gαi and Gαo subunits, i.e. Trp-258 in Gαi3 and Phe-259 in Gαo (Fig. 5A), accounts for the preferential binding of GIV to Gαi versuso (29). To determine whether this is the case for Calnuc, we investigated the effect of mutating Trp-258 in Gαi3 and Phe-259 in Gαo on the binding of these G proteins to Calnuc. GST-Calnuc bound robustly to purified wild-type His-Gαi3 but not to purified wild-type His-Gαo (Fig. 5B); this striking preference remained unchanged when Trp-258 in Gαi3 was mutated to Phe or when Phe-259 in Gαo was mutated to Trp (Fig. 5B). This indicates that Trp-258 in Gαi is not responsible for the preferential binding of Calnuc to Gαi versuso.

FIGURE 5.

FIGURE 5.

Lys-248 but not Trp-258 is responsible for preferential binding of Calnuc to Gαi3versuso. A, sequence alignment of Gαo, Gαi1, Gαi2, and Gαi3 indicating the Gαi3 and Gαo mutants studied. Rat Gαo, Gαi1, Gαi2, and Gαi3 sequences corresponding to the SwII and the α3 helix were obtained from the NCBI database and aligned using ClustalW. Conserved identical residues are shaded in black and similar residues in gray. The secondary structure elements (α = α-helix, β = β-sheet) indicated below the alignment are named according to their crystal structures. Residues within this region that are conserved among Gαi1, Gαi2, and Gαi3 but are different in Gαo were mutated in Gαi3 to the corresponding residues in Gαo (indicated below with arrows) or in Gαo to the corresponding residues in Gαi3 (indicated above with arrows). B, wild-type His-Gαi3·GDP (lane 1) and His-Gαi3·GDP W258F (lane 5) but not wild-type His-Gαo·GDP (lane 3) or His-Gαo·GDP F259W (lane 7) bind to GST-Calnuc. No binding of any of the Gα subunits loaded with GDP·AlF4 to GST-Calnuc was detected (lanes 2, 4, 6, and 8). 6 μg of His-Gαi3 (lanes 1 and 2), His-Gαo (lanes 3 and 4), His-Gαi3 W258F (lanes 5 and 6), or His-Gαo F259W (lanes 7 and 8) preloaded with GDP (lanes 1, 3, 5, and 7) or GDP and AlF4 (lanes 2, 4, 6, and 8) was incubated with ∼20 μg of purified GST-Calnuc immobilized on glutathione beads and analyzed as described in the legend for Fig. 2A. C, His-CalnucΔN binding to GST-Gαi3 K248M·GDP (Gαi3 Km (lane 4)) is reduced ∼80% compared with wild-type GST-Gαi3·GDP (Gαi3 WT, lane 3). No binding of His-CalnucΔN to GST (lane 2) or GDP·AlF4-loaded Gαi3 (lanes 5 and 6) is detected. 10 μg of His-CalnucΔN was incubated with purified GST (lane 2), wild-type GST-Gαi3 (lanes 3 and 5), or GST-Gαi3 K248M (lanes 4 and 6) preloaded with GDP (lanes 2–4) or GDP·AlF4 (lanes 5 and 6) immobilized on glutathione beads and analyzed as described in the legend for Fig. 2A. Input (lane 1), 1 μg of His-CalnucΔN. IB, immunoblot. D, wild-type His-Gαi3·GDP (Gαi3 WT (lane 4)) and His-Gαo M249K·GDP (Gαo MK (lane 6)) but not wild-type His-Gαo (Gαo WT (lane 5)) bind to GST-Calnuc. No binding of any of the Gα subunits to GST is detected (lanes 1–3). 6 μg of each His-Gα subunit preloaded with GDP was incubated with ∼20 μg of purified GST (lanes 1–3) or GST-Calnuc (lanes 4–6) immobilized on glutathione beads and analyzed as in the legend for Fig. 2A.

We reasoned that Lys-248 in Gαi could be responsible for the preferential binding to Gαi versuso because it is the only amino acid that is not conserved between the two Gα subunits in the Calnuc binding site (Fig. 5A), i.e. the α3/SwII cleft (Fig. 3). Mutation of Lys-248 in GST-Gαi3 to Met, the corresponding residue in Gαo, dramatically decreased His-CalnucΔN binding (Fig. 5C). Importantly, GST-Gαi3 K248M did bind to GIV, AGS3 (activator of G protein signaling 3), and Gβγ (Ref. 29 and data not shown), indicating that this mutation specifically affects Calnuc binding. Conversely, when Met-249 in His-Gαo was mutated to Lys, it enhanced its binding to GST-Calnuc compared with wild-type His-Gαo (Fig. 5D). Furthermore, structural analysis (supplemental Fig. S2A) revealed that the positively charged Lys-248 of Gαi3 might establish an electrostatic interaction with negatively charged Glu-314 of Calnuc. We hypothesized that inverting the charge of the Gαi3 Lys-248 alone would impair the Gαi3-Calnuc interaction by electrostatic repulsion of the Calnuc Glu-314 but that inverting the charges of these two residues simultaneously would restore the interaction by establishing an electrostatic attraction analogous to that found in the native situation. In fact, inversion of the charge of the Gαi3 Lys-248 by mutation to Glu abolished Gαi3 binding to wild-type Calnuc, and binding was restored if the charge of Calnuc Glu-314 was simultaneously inverted by mutation to Lys (supplemental Fig. S2B), suggesting that the electrostatic interaction between Gαi3 aa 248 and Calnuc aa 314 stabilizes Gαi3-Calnuc binding. These results demonstrate that although GIV and Calnuc have an overlapping binding site on Gα subunits, i.e. the α3/SwII cleft, and display preference for Gαi versuso, the critical residues in the Gα subunit that determine binding specificity are different.

Identification of Residues in Calnuc Required for Binding and Regulating Gαi

Calnuc, NUCB2, GIV and GIV-related peptides share hydrophobic residues in positions 3, 6 and 7 of the consensus sequence depicted in Fig. 1A. In the structure of the KB-752·Gαi1 complex these residues are packed against the hydrophobic cleft formed by the α3 helix and switch II to stabilize the interaction (Ref. 15 and Fig. 1B). We reasoned that residues in the same position might also be required for Calnuc and NUCB2 to bind Gαi3. We found that mutation of each of the corresponding residues in Calnuc, i.e. Leu-313, Phe-316, and Leu-317 to Ala dramatically reduced His-Gαi3 binding to GST-Calnuc (Fig. 6A). The double mutant L313A/L317A decreased the interaction even further than the single mutations (Fig. 6A, see high exposure blot). Similar findings were obtained for NUCB2 (Fig. 6B), indicating that these hydrophobic residues are required for both Calnuc and NUCB2 to interact with Gαi3. In addition, mutation of Gαi3 Trp-211 or Phe-215 in the predicted binding site for Calnuc (supplemental Fig. S3A) also disrupted the interaction (supplemental Fig. S3B), suggesting that they mediate a hydrophobic interaction with the Calnuc Leu-313, Phe-316, and Leu-317. These results indicate that the interaction of Calnuc and NUCB2 with Gαi3 requires the hydrophobic residues found in their conserved motif shared with GIV and GIV-related peptides.

FIGURE 6.

FIGURE 6.

Identification of critical residues in Calnuc required for binding Gαi3. A, His-Gαi3·GDP binds to wild-type GST-Calnuc (lane 3) but not to GST-Calnuc mutants L313A (lane 4), F316A (lane 5), L317A (lane 6), or L313A/L317A (lane 7) or GST alone (lane 2). 6 μg of His-Gαi3 preloaded with GDP (30 μm) was incubated with ∼20 μg of purified GST (lane 2), wild-type GST-Calnuc (lane 3), or GST-Calnuc mutants L313A (lane 4), F316A (lane 5), L317A (lane 6), or L313A/L317A (lane 7) immobilized on glutathione beads and analyzed as described in the legend for Fig. 2A. Input (lane 1), 0.1 μg of His-Gαi3. IB, immunoblot. B, His-Gαi3·GDP binds to wild-type GST-NUCB2-(173–333) (lane 3) but not to GST-NUCB2 mutants F318A (lane 4) or L315A/L319A (lane 5) or to GST alone (lane 2). 6 μg of His-Gαi3 preloaded with GDP (30 μm) was incubated with ∼20 μg of purified GST (lane 2), wild-type GST-NUCB2 (lane 3), or GST-Calnuc mutants L313A (lane 4) or L315A/L319A (lane 5) immobilized on glutathione beads and analyzed as described in the legend for Fig. 2A. Input (lane 1), 0.1 μg of His-Gαi3.

We next investigated the effect of Calnuc and NUCB2 on G protein activation. For this we measured the steady-state GTPase activity of His-Gαi3 (which depends directly on the rate of nucleotide exchange (29, 35)) in the presence of wild-type His-CalnucΔN or His-CalnucΔN L313A/L317A, which has dramatically impaired binding to Gαi3 (Fig. 6A) (negative control). His-CalnucΔN was used instead of full-length His-Calnuc because the protein concentrations used in these experiments were achievable only for the truncated protein, which expresses at higher yields in bacteria (see “Experimental Procedures”). Wild-type CalnucΔN but not CalnucΔN L313A/L317A increased the rate of steady-state GTP hydrolysis (Fig. 7A). Similarly, wild-type GST-NUCB2 but not its binding-deficient mutant, L315A/L319A, also increased the steady-state GTPase activity of Gαi3 (Fig. 7B). Other mutants of the Gα-binding motif such as Calnuc F316A and NUCB2 F318A also impaired Gαi3 activation when compared with their respective wild-type controls (supplemental Fig. S4), suggesting that Calnuc and NUCB2 are GEFs for Gαi3 and that they work via their conserved Gα-binding motif. Wild-type CalnucΔN and NUCB2 increased the GTPase activity of His-Gαi3 1.74- ± 0.18-fold (n = 6) and 1.76- ± 0.13-fold (n = 3), respectively, at the maximal concentration tested (Fig. 7C). The EC50 values were 7.3 ± 1.0 μm and 4.0 ± 1.0 μm (Fig. 7C), which are in good agreement with their respective Kd values for Gαi3 binding (Fig. 2C). To further validate the role of Calnuc as a GEF, we performed GTPγS binding experiments, which are a direct measure of GDP for GTP exchange activity. Incubation of His-Gαi3 in the presence of CalnucΔN increased the initial rate of GTPγS binding 1.70- ± 0.10-fold (n = 4) compared with the G protein alone (Fig. 7D). Taken together, these results indicate that the Gαi-binding motif in Calnuc and NUCB2 has GEF activity toward Gαi3.

Effect of Calcium Binding to Calnuc and NUCB2 on Their Interaction with Gαi3

The domain of Calnuc containing both EF-hands is known to be disorganized in the absence of Ca2+ and to adopt a globular conformation upon binding of the divalent cation (34). Analysis of the structure of calcium-bound Calnuc revealed that the residues that interact with Gαi3, i.e. Leu-313, Phe-316, and Leu-317 (Fig. 6A), are also utilized to make an intramolecular contact in the calcium-bound conformation (Fig. 8A), suggesting that Calnuc would not be able to interact with Gαi3 upon binding of Ca2+. We found this to be the case, because neither Calnuc nor NUCB2 bound Gαi3 in the presence of excess CaCl2 (Fig. 8, B and C). No difference was observed when the experiment was performed in the presence of excess MgCl2 or LiCl (data not shown), indicating that the observed effect is specific for Ca2+. We also investigated the effect of Ca2+ on the GEF activity of Calnuc and found that increasing concentrations of Ca2+ inhibited the increase in GTPγS binding to Gαi3 promoted by Calnuc with an IC50 of 1.2 ± 0.12 μm (n = 3) (Fig. 8D), a value similar to the previously reported Kd of Calnuc for Ca2+. Finally, we investigated the effect of elevating intracellular Ca2+ levels on the interaction between Calnuc and Gαi3 in cultured cells. COS-7 cells were co-transfected with Gαi3-FLAG and a truncated Calnuc (ΔSS-Calnuc-CFP), lacking the signal sequence which is present predominantly in the cytosol (26). Cells were stimulated with thapsigargin (which elevates the cytosolic levels of Ca2+ by blocking the endoplasmic reticulum Ca2+ pump) or ATP (which activates purinergic receptors at the cell surface) (22), and immunoprecipitation was carried out using anti-FLAG IgG followed by immunoblotting for Calnuc. We found that ΔSS-Calnuc-CFP co-immunoprecipitated with Gαi3 exclusively in nonstimulated cells, but it was virtually abolished after stimulation with either thapsigargin or ATP (Fig. 8E). Co-immunoprecipitation of Gβγ with Gαi3-FLAG was not affected by thapsigargin or ATP, indicating that elevation of the intracellular levels of Ca2+ specifically affects the interaction of Gαi3 with Calnuc but not other Gα-binding proteins. These results suggest that elevation of intracellular Ca2+ levels can efficiently disrupt the interaction between Calnuc and Gαi3 in living cells, corroborating our observations in vitro. Taken together, these data indicate that calcium binding can promote conformational changes in Calnuc (and presumably also in NUCB2) that block its interaction with Gα subunits in vitro and in living cells (Fig. 8F), subsequently inhibiting its GEF activity.

DISCUSSION

In this work we identify a new class of G protein-binding motif with defined structural features. This motif is found in two closely related proteins, Calnuc and NUCB2, and was previously found in another unrelated protein, GIV, and in the synthetic peptides KB-752 and GSP, shown previously to have GEF activity for Gαi (15, 33). It consists of a relatively disordered N-terminal region followed by an α-helix that docks onto the α3/SwII cleft of the Gαi subunits only in the inactive conformation to enable GEF activity in vitro. We named this signature sequence the GBA motif (for Gα-binding and -activating motif). We propose that the conserved GBA motif found in native proteins is a signature structure that defines a new family of G protein regulators with GEF activity, in the same fashion as the GoLoco/GPR motif or the RGS box define families of proteins with GDI or GTPase-activating protein activity, respectively. An important observation is that the GBA motif in Calnuc is evolutionarily conserved across species from sponges to man (supplemental Fig. S1), and the Caenorhabditis elegans orthologues of Calnuc and the Gα subunits have been shown to interact (36), suggesting that its function as a Gα-binding motif is also evolutionarily conserved. This evolutionary conservation suggests a selection imposed by a crucial biological function associated with the interaction with Gαi. It is interesting that a similar consensus motif was found in two synthetic peptides, KB-752 and GSP, which were identified by two different in vitro approaches, phage display of random sequence peptides (15) and iterative optimization of in vitro mRNA-translated peptides (33). In both cases the selection is determined solely by the chemical properties of the peptides and not their biological function. These observations suggest that the sequences found in vivo in the GBA motif of Calnuc, NUCB2, and GIV have highly optimized chemical properties for Gαi binding.

Based on the sequences of Calnuc, NUCB2, and GIV in different species (supplemental Fig. S1 and Ref. 14) and related synthetic peptides (15, 33), we propose that the GBA motif can be defined by a conserved core sequence of seven amino acids (Fig. 1A), Ψ-[S/T]-[Φ/Ψ]-X-[D/E]-F-Ψ, in which Ψ are aliphatic residues and Φ are aromatic residues. Residues in positions 3, 6, and 7 in this consensus motif, i.e. Leu-313, Phe-316, and Leu-317 in Calnuc, correspond to hydrophobic residues aligned on one side of the α-helical part of the motif, which are used to stabilize the interaction with Gαi by packing against the α3/SwII hydrophobic cleft. Residues in positions 2 and 5 form a hydrogen bond in the structures of KB-752 and Calnuc, which is required for the motif to adopt its helical conformation. This design for molecular coupling resembles that observed for other signaling interfaces. For example, A-kinase-anchoring proteins (AKAPs) are characterized by a signature motif that forms an aliphatic helix that docks onto a hydrophobic pocket on the regulatory subunit of cAMP-dependent protein kinase (PKA) (37), and the N-terminal region of the GoLoco/GPR motif, also binds to the α3/SwII hydrophobic cleft of Gαi subunits via an aliphatic helix (10).

Our results also provide the structural basis for the regulation of Calnuc and NUCB2 binding to and activation of Gαi subunits by calcium. Calnuc is the major calcium-binding protein in the lumen of Golgi cisternae, where it regulates the intracellular calcium stores (21, 22). On the other hand, there is a cytosolic pool of Calnuc that interacts directly with Gαi3 (26). NUCB2 has been described as sharing a similar subcellular distribution (20). The regulation of the Calnuc/NUCB2-Gαi interaction by Ca2+ described in this work is not surprising considering that the Gα-binding motif on Calnuc overlaps with the EF-hands responsible for calcium binding. Our finding that Gαi binding to Calnuc and NUCB2 is impaired by calcium binding is compatible with previous observations by NMR indicating that when calcium-bound, the Calnuc EF-hands fold into a globular domain that hides the Gαi-binding residues, whereas in the absence of calcium this domain is disordered and probably exposes the Gαi-binding motif (Fig. 8F). Thus, we propose that the conformational changes in Calnuc and NUCB2 that occur upon Ca2+ binding regulate their interaction with the G protein and its subsequent activation. This mode of regulation by Ca2+ is consistent with our results presented here indicating that Calnuc and Gαi3 interact in the cytosol of cells under resting conditions (in accord with our own previous observation using FRET and live cell microscopy (26)) but not upon stimulation with thapsigargin or ATP (Fig. 8E). This is probably because in resting conditions the cytosolic concentration of free Ca2+ (50–100 nm) is significantly lower than the Kd value of Calnuc for Ca2+ binding (∼7 μm, (22)), thereby allowing the interaction of calcium-free Calnuc with Gαi3, whereas upon stimulation with thapsigargin or ATP the intracellular levels of Ca2+ are increased and calcium-bound Calnuc cannot interact with Gαi3. It will be important in the future to ask whether the regulation of the Calnuc-Gαi3 interaction by Ca2+ might influence the interplay between G protein- and calcium-dependent signaling, two major signaling events that regulate a multitude of cellular functions.

Our data also unveiled the structural basis for the state-dependent binding of Calnuc and NUCB2 to Gαi subunits. Based on the structures of Gαi1 and other Gα subunits bound to GTPγS and GDP- AlF4 (38, 39), the hydrophobic cleft circumscribed by the α3 helix and the switch II is occluded when the G protein adopts the active conformation, thereby hindering its interaction with Calnuc and NUCB2 by steric clashes. From this we concluded that conformational changes of Gαi3 upon activation determine its interaction with Calnuc and NUCB2. We previously reported that Calnuc binds to a site different from the α3/SwII cleft (i.e. the α5 helix) of Gαi3 by using C-terminal truncations of the G protein (25). Although we cannot rule out the presence of two binding sites for Calnuc on Gαi subunits, one likely explanation for the previous results is that truncation of the Gαi C terminus promotes constitutive activation of the G protein (40) which in light of the data presented here would abolish its interaction with Calnuc and NUCB2.

The studies presented here also provide insights into the specific features of the Calnuc-Gα subunit interface and its differences from another GBA motif-containing protein, i.e. GIV. Both Calnuc and GIV bind preferentially to Gαi subunits over Gαo or Gαs, but Calnuc shows preference for Gαi1 and Gαi3 over Gαi2, whereas GIV binds equally to Gαi1, Gαi2, and Gαi3 in vitro (14). The basis for the preference of Calnuc for Gαi1 and Gαi3 over Gαi2 is still unclear, because all Gαi subunits have identical residues in the switch II and the α3 helix (Fig. 5A), which based on our results presented here is a major binding site for Calnuc on the G protein. It is possible that other residues of the G protein outside of this major binding surface, i.e. the α3/SwII cleft, may also determine the specificity of binding by making additional contacts, as reported for other G protein regulators with preference for Gαi1 and Gαi3 over Gαi2 such as GAIP/RGS19 (41), RGS14 (42, 43), and RGS12 (44). As in the case of GIV (29), binding of Calnuc to Gαo is marginal compared with binding to Gαi3. We provide evidence here that the preferential binding of Calnuc to Gαi over Gαo is determined by Lys-248, located in the middle of the α3 helix of the G protein, but not by Trp-258, located in the α3/β5 loop, which we have previously shown to be responsible for the preferential binding of GIV to Gαi versuso (29). Based on the results presented here on Calnuc (Figs. 5 and 6 and supplemental Figs. S2 and S3) and our own published (14, 29) and unpublished data on GIV, we propose that conserved hydrophobic residues in Calnuc and the GIV GBA motif are required to dock onto a common spot of Gαi3, i.e. the α3/SwII hydrophobic cleft, whereas nonconserved residues establish a set of contacts with the G protein that is different for Calnuc or GIV (see details in supplemental Fig. S5). These variations in the common theme highlight the uniqueness of the interfaces formed between different GBA motif-containing proteins and the G protein, which may be relevant for achieving specificity in the pharmacological targeting of these interfaces for therapeutic purposes, as proposed for GIV (14, 29).

Our results suggest a role for Calnuc and NUCB2 as regulators of G protein activity. The affinity of Calnuc and NUCB2 for Gαi3 (Kd ∼4 and ∼1 μm, respectively) is lower than that of GIV (Kd ∼300 nm, data not shown) but similar to the GEF peptide KB-752 (Kd ∼4 μm (15)) and other G protein regulators such as the GDI proteins LGN (Kd ∼6 μm (45)) and G18/AGS4 (Kd ∼2.5 μm (46)). Like GIV and related synthetic peptides, Calnuc and NUCB2 possess GEF activity in vitro, indicating that this is a common feature associated with the conserved GBA motif. While this manuscript was in preparation, Kapoor et al. (47) reported that Calnuc possesses GDI activity toward Gαi1. Although the reason for the discrepancy between their work and ours is not clear, one possible explanation is the different experimental conditions used; specifically, Kapoor et al. (47) used ∼200–400-fold higher concentrations of G protein and nucleotide in their G protein activity assays than those used here and in most previous studies of this type (6, 7, 10, 14, 15, 29, 33, 40, 48) which might affect the enzymatic properties of the reaction studied. In addition, some of the evidence presented by Kapoor et al. (47) is based on spectroscopic studies with fluorescent nucleotide analogs, and this type of analysis has been reported to generate artifactual readouts (48) for peptides such as Calnuc that bind to the α3/SwII cleft (Fig. 3). By using the Gαi binding-deficient mutants L313A/L317A and F316A of Calnuc as a negative controls (Figs. 6 and S4A), we demonstrated that the observed increase in G protein activation can be attributed specifically to the GBA motif. The Calnuc interaction with and activation of Gαi3 occurs at relatively high concentrations in vitro, and its GEF activity is weaker than that observed for GIV or G protein-coupled receptors. However, our previously published data demonstrate that the interaction occurs in vivo because cytosolic Calnuc and Gαi3 bind to each other in living cells as determined by FRET and live cell imaging (26) and that Calnuc regulates the subcellular localization of Gαi3 (27), suggesting a functional role for the Calnuc-Gαi coupling in the physiological setting. Further investigations will be required to elucidate whether Gαi3 activation by Calnuc occurs in vivo and to determine the functional consequences of the interaction.

Supplementary Material

Supplemental Data

Acknowledgments

We thank Xianshi Cui and Steve Dowdy for synthesizing and purifying the Calnuc-(309–324) peptide, Sekar Menon and Susan Ferro-Novick for access to the FPLC apparatus used for protein purification, and David Siderovski for kindly providing the pMCSG7 vector. We also thank Michelle Adia and Qi Zhong for valuable technical assistance.

*

This work was supported, in whole or in part, by National Institutes of Health Grants DKI7780 and CA100768 (to M. G. F.).

Inline graphic

The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. S1–S5.

4
The abbreviations used are:
RGS
regulator of G protein signaling
GIV
Gα-interacting vesicle-associated protein
GEF
guanine nucleotide exchange factor
GDI
guanine nucleotide dissociation inhibitor
GPR
G protein-regulatory
aa
amino acid(s)
GBA
Gα binding and activating
GTPγS
guanosine 5′-3-O-(thio)triphosphate
SwII
switch II
CFP
cyan fluorescent protein
GSP
Galphas(s)-binding peptide.

REFERENCES

  • 1. Sato M., Blumer J. B., Simon V., Lanier S. M. (2006) Annu. Rev. Pharmacol. Toxicol. 46, 151–187 [DOI] [PubMed] [Google Scholar]
  • 2. Blumer J. B., Smrcka A. V., Lanier S. M. (2007) Pharmacol. Ther. 113, 488–506 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Siderovski D. P., Willard F. S. (2005) Int. J. Biol. Sci. 1, 51–66 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. De Vries L., Zheng B., Fischer T., Elenko E., Farquhar M. G. (2000) Annu. Rev. Pharmacol. Toxicol. 40, 235–271 [DOI] [PubMed] [Google Scholar]
  • 5. Ross E. M., Wilkie T. M. (2000) Annu. Rev. Biochem. 69, 795–827 [DOI] [PubMed] [Google Scholar]
  • 6. De Vries L., Fischer T., Tronchère H., Brothers G. M., Strockbine B., Siderovski D. P., Farquhar M. G. (2000) Proc. Natl. Acad. Sci. U.S.A. 97, 14364–14369 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Peterson Y. K., Bernard M. L., Ma H., Hazard S., 3rd, Graber S. G., Lanier S. M. (2000) J. Biol. Chem. 275, 33193–33196 [DOI] [PubMed] [Google Scholar]
  • 8. Tesmer J. J., Berman D. M., Gilman A. G., Sprang S. R. (1997) Cell 89, 251–261 [DOI] [PubMed] [Google Scholar]
  • 9. Soundararajan M., Willard F. S., Kimple A. J., Turnbull A. P., Ball L. J., Schoch G. A., Gileadi C., Fedorov O. Y., Dowler E. F., Higman V. A., Hutsell S. Q., Sundström M., Doyle D. A., Siderovski D. P. (2008) Proc. Natl. Acad. Sci. U.S.A. 105, 6457–6462 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Kimple R. J., Kimple M. E., Betts L., Sondek J., Siderovski D. P. (2002) Nature 416, 878–881 [DOI] [PubMed] [Google Scholar]
  • 11. Kimple A. J., Yasgar A., Hughes M., Jadhav A., Willard F. S., Muller R. E., Austin C. P., Inglese J., Ibeanu G. C., Siderovski D. P., Simeonov A. (2008) Comb. Chem. High Throughput Screen. 11, 396–409 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Sjogren B., Blazer L. L., Neubig R. R. (2010) Prog. Mol. Biol. Transl. Sci. 91, 81–119 [DOI] [PubMed] [Google Scholar]
  • 13. Le-Niculescu H., Niesman I., Fischer T., DeVries L., Farquhar M. G. (2005) J. Biol. Chem. 280, 22012–22020 [DOI] [PubMed] [Google Scholar]
  • 14. Garcia-Marcos M., Ghosh P., Farquhar M. G. (2009) Proc. Natl. Acad. Sci. U.S.A. 106, 3178–3183 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Johnston C. A., Willard F. S., Jezyk M. R., Fredericks Z., Bodor E. T., Jones M. B., Blaesius R., Watts V. J., Harden T. K., Sondek J., Ramer J. K., Siderovski D. P. (2005) Structure 13, 1069–1080 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Garcia-Marcos M., Jung B. H., Ear J., Cabrera B., Carethers J. M., Ghosh P. (2011) FASEB J. 22, 590–599 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Ghosh P., Garcia-Marcos M., Bornheimer S. J., Farquhar M. G. (2008) J. Cell Biol. 182, 381–393 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Anai M., Shojima N., Katagiri H., Ogihara T., Sakoda H., Onishi Y., Ono H., Fujishiro M., Fukushima Y., Horike N., Viana A., Kikuchi M., Noguchi N., Takahashi S., Takata K., Oka Y., Uchijima Y., Kurihara H., Asano T. (2005) J. Biol. Chem. 280, 18525–18535 [DOI] [PubMed] [Google Scholar]
  • 19. Weng L., Enomoto A., Ishida-Takagishi M., Asai N., Takahashi M. (2010) Cancer Sci. 101, 836–842 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Morel-Huaux V. M., Pypaert M., Wouters S., Tartakoff A. M., Jurgan U., Gevaert K., Courtoy P. J. (2002) Eur. J. Cell Biol. 81, 87–100 [DOI] [PubMed] [Google Scholar]
  • 21. Lin P., Le-Niculescu H., Hofmeister R., McCaffery J. M., Jin M., Hennemann H., McQuistan T., De Vries L., Farquhar M. G. (1998) J. Cell Biol. 141, 1515–1527 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Lin P., Yao Y., Hofmeister R., Tsien R. Y., Farquhar M. G. (1999) J. Cell Biol. 145, 279–289 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Miura K., Kurosawa Y., Kanai Y. (1994) Biochem. Biophys. Res. Commun. 199, 1388–1393 [DOI] [PubMed] [Google Scholar]
  • 24. Gilchrist A., Au C. E., Hiding J., Bell A. W., Fernandez-Rodriguez J., Lesimple S., Nagaya H., Roy L., Gosline S. J., Hallett M., Paiement J., Kearney R. E., Nilsson T., Bergeron J. J. (2006) Cell 127, 1265–1281 [DOI] [PubMed] [Google Scholar]
  • 25. Lin P., Fischer T., Weiss T., Farquhar M. G. (2000) Proc. Natl. Acad. Sci. U.S.A. 97, 674–679 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Weiss T. S., Chamberlain C. E., Takeda T., Lin P., Hahn K. M., Farquhar M. G. (2001) Proc. Natl. Acad. Sci. U.S.A. 98, 14961–14966 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Lin P., Fischer T., Lavoie C., Huang H., Farquhar M. G. (2009) Mol. Neurodegener. 4, 15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Gump J. M., June R. K., Dowdy S. F. (2010) J. Biol. Chem. 285, 1500–1507 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Garcia-Marcos M., Ghosh P., Ear J., Farquhar M. G. (2010) J. Biol. Chem. 285, 12765–12777 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Stols L., Gu M., Dieckman L., Raffen R., Collart F. R., Donnelly M. I. (2002) Protein Expr. Purif. 25, 8–15 [DOI] [PubMed] [Google Scholar]
  • 31. Studier F. W. (2005) Protein Expr. Purif. 41, 207–234 [DOI] [PubMed] [Google Scholar]
  • 32. De Vries L., Elenko E., McCaffery J. M., Fischer T., Hubler L., McQuistan T., Watson N., Farquhar M. G. (1998) Mol. Biol. Cell 9, 1123–1134 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Austin R. J., Ja W. W., Roberts R. W. (2008) J. Mol. Biol. 377, 1406–1418 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. de Alba E., Tjandra N. (2004) Biochemistry 43, 10039–10049 [DOI] [PubMed] [Google Scholar]
  • 35. Mukhopadhyay S., Ross E. M. (2002) Methods Enzymol. 344, 350–369 [DOI] [PubMed] [Google Scholar]
  • 36. Cuppen E., van der Linden A. M., Jansen G., Plasterk R. H. (2003) Comp. Funct. Genomics 4, 479–491 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Welch E. J., Jones B. W., Scott J. D. (2010) Mol. Interv. 10, 86–97 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Coleman D. E., Berghuis A. M., Lee E., Linder M. E., Gilman A. G., Sprang S. R. (1994) Science 265, 1405–1412 [DOI] [PubMed] [Google Scholar]
  • 39. Noel J. P., Hamm H. E., Sigler P. B. (1993) Nature 366, 654–663 [DOI] [PubMed] [Google Scholar]
  • 40. Denker B. M., Schmidt C. J., Neer E. J. (1992) J. Biol. Chem. 267, 9998–10002 [PubMed] [Google Scholar]
  • 41. Woulfe D. S., Stadel J. M. (1999) J. Biol. Chem. 274, 17718–17724 [DOI] [PubMed] [Google Scholar]
  • 42. Shu F. J., Ramineni S., Amyot W., Hepler J. R. (2007) Cell. Signal. 19, 163–176 [DOI] [PubMed] [Google Scholar]
  • 43. Mittal V., Linder M. E. (2004) J. Biol. Chem. 279, 46772–46778 [DOI] [PubMed] [Google Scholar]
  • 44. Webb C. K., McCudden C. R., Willard F. S., Kimple R. J., Siderovski D. P., Oxford G. S. (2005) J. Neurochem. 92, 1408–1418 [DOI] [PubMed] [Google Scholar]
  • 45. McCudden C. R., Willard F. S., Kimple R. J., Johnston C. A., Hains M. D., Jones M. B., Siderovski D. P. (2005) Biochim. Biophys. Acta 1745, 254–264 [DOI] [PubMed] [Google Scholar]
  • 46. Kimple R. J., Willard F. S., Hains M. D., Jones M. B., Nweke G. K., Siderovski D. P. (2004) Biochem. J. 378, 801–808 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47. Kapoor N., Gupta R., Menon S. T., Folta-Stogniew E., Raleigh D. P., Sakmar T. P. (2010) J. Biol. Chem. 285, 31647–31660 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. Willard F. S., Siderovski D. P. (2006) Biochem. Biophys. Res. Commun. 339, 1107–1112 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplemental Data

Articles from The Journal of Biological Chemistry are provided here courtesy of American Society for Biochemistry and Molecular Biology

RESOURCES